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Abstract 
Background: Reducing the burden of suffering caused by preventable diseases in 
populations is a central goal in public health. Screening is a prevention strategy the aim 
of which is to identify pre-symptomatic conditions, thus enabling earlier intervention in 
the hope to reduce morbidity and mortality. Yet screening may also cause harm, one of 
which is the psychological effects of receiving a diagnosis – diagnostic labeling. 
Aim: To conduct a systematic review of studies assessing psychological state after a 
diagnosis of either prostate cancer or abdominal aortic aneurysm (AAA). 
Method:  A comprehensive literature search of studies published from 2002 to 2015 
was conducted. Main inclusion criteria were that study participants had recently been 
diagnosed with either prostate cancer or AAA and their psychological state was 
assessed. Randomized controlled trials, observational cohort studies, cross-sectional 
studies, and qualitative studies were eligible. All studies were critically appraised and 
reviewed by at least 2 trained investigators. Disagreements were resolved by a third 
senior investigator. 
Results: Forty studies were included in the analysis. All eight qualitative studies on both 
prostate cancer and AAA showed some evidence of adverse psychological effect of 
detection of the condition. The results of the 32 quantitative studies were more mixed, 
with approximately half of the studies suggesting presence of psychological problems in 
newly diagnosed individuals. For a third of the studies the presence of psychological 
problems could not be conclusively evaluated due to study design (lack of comparison 
group) and presentation of the results (average scores only). 
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Conclusions: Few studies were designed to evaluate the effect of receiving a 
diagnosis of prostate cancer or AAA. The results suggest that diagnostic labeling may 
cause some degree of psychological harm in at least some individuals; more research is 
needed to better estimate the frequency and severity of these harms. Labeling is a 
potential psychological harm that should be considered when planning screening 
programs. 
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INTRODUCTION 
Public health is concerned with protecting and improving the health of entire 
populations. This includes promotion of healthy lifestyles, developing health-promoting 
policies, and conducting research on the determinants of health and disease. Reducing 
premature mortality and the burden of suffering caused by disease and disability is one 
of the central goals of public health.  
 
There are two broad types of prevention strategies: population strategies and high-risk 
strategies (Rose 2001). In a population strategy, we hope to change the whole 
population distribution of the disease or outcome in a more favorable direction. This is 
particularly worthwhile when most cases come from a large number of individuals at low 
risk for the condition. A high-risk strategy is preferable when most cases come from 
smaller group of individuals at high risk for the disease. These strategies aim to first 
identify these individuals and then intervene to prevent adverse health outcomes. 
Screening is one popular strategy for achieving this. 
 
Ideally, screening for a condition allows us to detect and treat asymptomatic cases 
before disease progression. Consequently, screening can prevent suffering, disability, 
or death through early intervention (Figure 1a-b). The potential benefits of screening 
programs are widely recognized. Cancer screening, in particular, is embraced by the 
public (Schwartz et al. 2004). Yet, in recent years the potential harms of screening have 
increasingly been acknowledged (Woolf, Harris 2012, Harris et al. 2011). It has become 
clear that the expected benefits should be carefully weighed against potential harms 
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before initiating population screening for a condition (Woolf, Harris 2012, Harris et al. 
2011). 
 
Potential harms of screening can be both physical and psychological (Harris et al. 
2014). Both the screening itself and the diagnostic work-up following a positive 
screening result can cause either physical harm or adverse psychological effects, such 
as anxiety and fear, among the individuals being screened. False positive screening 
results are considered particularly worrisome, since they force healthy individuals to go 
through extensive diagnostic procedures. False negative results, on the other hand, 
may give false reassurance and delay treatment seeking when symptoms occur.  
 
False positive and negative screening results arise because no screening tool is perfect. 
But harms of screening are not limited to the false results. Even screening with a 
hypothetical perfect instrument, i.e. one with 100% sensitivity and specificity and 
consequently no false positive of negative results, may cause harm. The reason is that, 
whereas the purpose of screening is to detect asymptomatic conditions to enable early 
treatment, not all individuals being diagnosed will benefit from receiving treatment. For 
them, receiving a diagnosis may cause more harm than benefit (Woolf, Harris 2012, 
Harris et al. 2011). 
 
Individuals unlikely to benefit from being diagnosed with an asymptomatic condition fall 
into three categories. First, those with a lethal disease the prognosis of which will not 
improve with early detection and treatment. This is true for many metastasized cancers 
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(Figure 1c). Second, those with a slowly progressing disease or “precondition” that 
would never have caused any harm or even been known to the individual. This applies 
for example to some forms of localized cancer. Detection of such conditions is often 
referred to as overdiagnosis (Figure 1d). Third, those who would fare equally well were 
their condition detected and treated at a later, symptomatic stage (Figure 1e) (Harris et 
al. 2011). 
 
Unnecessary invasive treatment of individuals who do not benefit from it has been 
recognized as a potential harm of screening programs, especially for conditions such as 
prostate cancer, ductal carcinoma in situ of the breast, and small abdominal aortic 
aneurysm, which may progress very slowly or not at all during the patient’s lifetime, but 
the treatment of which are invasive (Harris, Sheridan & Kinsinger 2012, Welch, Passow 
2014, LeFevre, U.S. Preventive Services Task Force 2014, Lin et al. 2008). A less 
recognized harm afflicted to these individuals is that caused by being diagnosed, which 
in itself may have a negative effect on wellbeing and psychological health. This is 
known as ‘diagnostic labeling’ (Figure 1). 
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Figure 1. Psychological harms of screening 
 
Figure 1. There are various benefits (green) and harms (red) of screening.  This figure 
illustrates the time interval when psychological harms may occur due to early labeling 
from screening. (S) An individual is screened.  (a) Screening prevents symptoms or 
disability.  (b) Screening prevents early death.  (c) Screening resulted in early/diagnostic 
labeling of a person with lethal disease.  (d) Screening resulted in overdiagnosis and 
labeling of person who would not have had symptoms or died from the disease that was 
screened for, making it appear as if screening prevented death. (e) Screening resulted 
in early/diagnostic labeling of a person who would have faired the same if diagnosed at 
a symptomatic state. Figure drawn by Yi Yang. 
  
Few studies have examined the effects of diagnostic labeling. Considerable 
psychological distress has been observed in individuals after they received a cancer 
diagnosis (Steinberg et al. 2009, Zabora et al. 2001). The same appears to be true for 
arterial hypertension: even in the absence of symptoms, being diagnosed with 
hypertension associates with increased absence from work (Haynes et al. 1978), poor 
self-rated health (Bloom, Monterossa 1981, Barger, Muldoon 2006), depressive 
symptoms, and psychological distress (Hamer et al. 2010, Bloom, Monterossa 1981). 
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Further, the knowledge of renal disease has been shown to associate with elevated 
mortality, even accounting for other factors that could affect prognosis (Whaley-Connell 
et al. 2012). Finally, recent findings from a large prospective cohort study showed that 
awareness opposed to ignorance of hypothyroidism, diabetes mellitus, and 
hypertension were associated with poor perceived health, suggesting an adverse effect 
of labeling (Jorgensen et al. 2015). 
 
In the context of screening, diagnostic labeling may cause unnecessary suffering to 
those with a slowly progressing disease they would otherwise never have known about. 
It may also cause harm to those with incurable disease and those who could 
successfully be treated when symptomatic, as these individuals will have to live longer 
with the diagnostic label and knowledge of the disease compared to if they were 
diagnosed after developing symptoms. 
 
Diagnostic labeling is particularly problematic in disorders that often remain 
asymptomatic for a long period of time and may never even progress to symptomatic 
conditions. Prostate cancer and abdominal aortic aneurysms (AAA) are examples of 
such disorders. Both conditions are commonly detected through screening and many 
people diagnosed are not immediately treated, but rather monitored for disease 
progression (often referred to as active surveillance or watchful waiting) (Moll et al. 
2011, Thompson et al. 2007). Both prostate cancer and AAAs are likely to be 
overdiagnosed, causing diagnostic labeling of asymptomatic individuals. 
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To better understand the potential psychological effects of diagnostic labeling, we 
conducted a systematic review of studies addressing quality of life and psychological 
distress shortly after receiving a diagnosis of either localized prostate cancer of an AAA. 
 
METHODS 
This master’s paper is a summary of the systematic review process, which was 
conducted as a team effort. A working group consisting of physicians and medical 
students carried out the systematic review steps, as described below. The summary is 
written by me (Linda Mustelin) and the discussion and conclusions are my original work, 
with input from my first and second reader. 
 
Data sources and searches 
A research librarian searched PubMed, Cumulative Index of Nursing and Allied Health 
Literature (CINAHL) via EBSCO, and PsycINFO via EBSCO for articles on prostate 
cancer published in 2002-2014 (Appendix A).  In September 2015, a bridge search was 
conducted in the same databases to find additional prostate cancer articles that were 
published from 2002-8/31/2015 (Appendix B).  For AAA, the search was conducted 
through the same databases from 2002-2015 (Appendix C) 
 
Study selection 
All articles identified in our searches for both prostate cancer and AAA were first 
reviewed at the abstract level by at least 2 reviewers following predefined inclusion and 
exclusion criteria.   
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The main inclusion criteria were: (1) diagnosis of either localized (non-metastatic) 
prostate cancer or AAA, (2) no active treatment started or anticipated (the patients were 
either undecided regarding treatment or had decided to undergo active surveillance 
(AS) or watchful waiting (WW), (3) psychological state was measured preferably within 
3 months or, for groups, at a mean of no more than 6 month since diagnosis. We also 
included studies where time since diagnosis was not reported, but wording such as 
“recent diagnosis” was used or the patients were assessed before their first clinic 
appointment. Studies with patients anticipating or undergoing different treatments were 
included if those in AS/WW were analyzed separately or constituted more than half of 
the study population. Inclusion and exclusion criteria are further detailed in Appendix D. 
 
The reviewers included abstracts for full-text review if they met inclusion criteria and did 
not meet exclusion criteria or if they did not contain sufficient information to determine 
eligibility. Abstracts that at least one reviewer included were reserved for full-text review.  
Two investigators independently performed full-text review of all included studies to 
further exclude papers that did not meet the inclusion criteria. Disagreements between 
the two full-text reviewers about inclusion or exclusion were resolved by a third senior 
reviewer.  
 
Working group 
Abstract and full-text reviewers: Linda Mustelin, Yi Yang, Malika Rakhmankulova, 
Kimmy Vuong, Anne Cotter. Supervisor and senior reviewer: Russell Harris. Additional 
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guidance in the early stages of the project was given by Colleen Barclay, who also 
prepared the original spreadsheets for abstract review and downloaded the articles 
included for full-text review. 
 
Focus of the present paper 
This masters paper analyzes all included quantitative studies, except for registry 
studies, which were excluded from the present analysis. The eight qualitative studies 
were also analyzed. 
 
Evaluation of psychological problems 
We first classified the included papers into those showing no evidence of psychological 
problems and those indicating at least some degree of psychological problems. For 
studies with a control group, evidence of psychological problems was defined as 
diagnosed individuals having statistically significantly higher levels of psychological 
distress than control subjects. For studies with pre- and post-diagnosis measurements, 
evidence of psychological problems was defined as a statistically significant increase in 
psychological distress following diagnosis. For studies lacking a control group, evidence 
of psychological problems was defined as the presence of psychological distress either 
as compared to clinical thresholds or reported population norms. If a study reported 
results in such a way that the presence of psychological distress could not be 
determined (e.g. only mean values for psychological measures without any comparison 
group or contrast to population norms), the study was classified as uncertain regarding 
evidence of psychological problems. 
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Studies showing at least some degree of psychological problems were further classified 
according to frequency of problems. Frequency was classified as low (<5%), moderate 
(5% to 25%) and high (>25%) according to what proportion of the study population 
experienced problems. The boundaries of the categories were based on group 
consensus and were established to facilitate interpretation of the results.  
 
Analytic vs. descriptive studies 
The studies included after full-text review were classified as either analytic or 
descriptive. A study was classified as analytic if psychological state was measured both 
before and after diagnosis or if it had a control group consisting of individuals without a 
diagnosis. This group could comprise community volunteers, individuals not invited to 
screening, or individuals that were screened but did not have the disorder they were 
screened for. All other studies were classified as descriptive, including trials with control 
groups that were not relevant for our study question. These included, for example, trials 
of the effect of educational interventions among patients, studies looking at racial 
differences, and studies comparing different treatment modalities. 
 
RESULTS 
Figure 2 presents the study selection process. A total of 32 quantitative studies met 
inclusion criteria by either double reviewer consensus or by senior investigator review.  
Of these, 27 were prostate cancer studies (6 analytic, 21 descriptive) and 5 were AAA 
studies (1 analytic, 4 descriptive). Eight qualitative studies were included (5 prostate 
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cancer studies and 3 AAA studies). Approximately half of the quantitative studies 
(15/32, 47%) found some evidence of psychological problems after an AAA or prostate 
cancer diagnosis. All qualitative studies showed evidence of psychological problems. 
Figure 2. Flowchart of study selection 
 
14 
Analytic studies 
Analytic studies are presented in Table 1. We identified only one analytic study of AAA 
diagnosis. This study had mixed results, with a statistically significant difference for the 
SF-36 mental component summary between those diagnosed with AAA and those who 
were screen-negative, but no other differences using other psychological measures. 
Further, the mean scores for the diagnosed individuals corresponded closely to those of 
the controls that were not screened.  
 
Four out of six analytic prostate cancer studies found evidence of psychological 
problems; for the two studies reporting the proportion of individuals experiencing 
problems, the frequency was moderate (5-25%). Both of the studies that found no 
evidence of psychological problems compared mean quality of life or distress scores 
among men with elevated PSA levels before the prostate biopsy and after confirmed 
diagnosis.  
 
Descriptive AAA studies 
One out of four descriptive AAA studies showed evidence of psychological problems in 
diagnosed individuals (Table 2). The frequency of problems was classified as moderate, 
as 24.6% of the patients were anxious or depressed. The other three studies only 
reported mean scores for the psychological measures without interpretations or 
information on clinical cut-offs, and the presence of problems could therefore not 
conclusively be evaluated. 
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Descriptive prostate cancer studies 
Ten out of 21 descriptive prostate cancer studies found some evidence of psychological 
problems among diagnosed individuals (Table 3). The frequency of problems was high 
(>25%) in three studies, moderate (5-25%) in six studies and low (<5%) in one study. 
However, given that these studies did not have a control group, we cannot be sure that 
the observed psychological problems were caused by the diagnosis.  
 
More than a third (8/21, 38%) of the studies reported only mean scores for 
psychological measures among the patients, without comparison to the general 
population and without reporting the proportion of subjects scoring above clinical 
thresholds. Although the mean values were within the normal range, we cannot rule out 
that some individuals experienced psychological problems. Three studies compared the 
mean values of psychological measures among diagnosed patients to previously 
reported results from the general population and found that the patients had on average 
more favorable scores than would have been expected based on population norms. 
 
Qualitative studies 
All six quantitative studies analyzed (3 AAA studies and 3 prostate cancer studies) 
showed evidence of psychological problems among diagnosed patients. A summary of 
findings from the qualitative studies is presented in Table 4. In-depth interviews with 
individuals diagnosed with AAA or prostate cancer revealed that many of them 
experienced anxiety, worry, and distress, as well as feelings of hopelessness, shock, 
and guilt.  
Table&1.&Analytic&papers&on&AAA&and&prostate&cancer.&
First&Author&
(Year)&
Disorder& Type&of&
comparison&
Number&of&
participants&
Population!(Sex;!
age;!region)&
Recruitment/Type&of&
sample&of&subjects!&
Comparison&group&
and/or&time&points&
Outcomes& &
Instruments&&
Summary&of&results&& Evidence&of&
psychological&
problems,&
frequency&
The!
Multicentre!
Aneurysm!
Screening!
Study!Group!
(2002)!
AAA! Diagnosed!
vs.!
Comparison!
group.!RCT.!
599!with!AAA,!631!
screenJnegatives,!
726!nonJscreened!
controls!
Men;!65J74;!four!
centers!in!the!UK!
CommunityJbased.!
Subjects!were!
randomly!allocated!to!
either!receive!an!
invitation!for!an!
abdominal!ultrasound!
scan!or!not.!
Two!control!groups:!1.!
Those!who!were!not!
invited!for!screening,!!!
2.!Those!who!screened!
negative.!
Time!of!measurement:!6!
weeks!after!screening!
Outcomes:!Depression,!
anxiety,!QoL!
Instruments:!HADS,!STAI,!
SFJ36!
CutJoffs:!Depression:!15!
(scale!0J21),!Anxiety:!42!
(scale!20J80).!!
At!six!weeks!after!screening:!!
State!anxiety:!ScreenJpositives:!30.9,!ScreenJnegatives!29.5!
(p=0.02),!NonJscreened!31.5!
Depression:!ScreenJpositives!3.3,!ScreenJnegatives!3.0!
(p=0.09),!NonJscreened!3.5!
SFJ36!MCS:!ScreenJpositives!49.8,!ScreenJnegatives!51.5!
(p=0.003),!NonJscreened!50.0!
Mixed!
Ishihara!
(2006)!
PCA! Pre!and!
post!
diagnosis!!
141!screened,!73!
with!PCA.!100!
(70.9%)!
participated.!
Men;!71.8!(7.4);!
Japan!
Outpatients!who!were!
suspected!to!have!
prostate!cancer!as!a!
result!of!screening!
Timepoints:!Before!
biopsy!and!after!
disgnosis!
Outcomes:!QoL!
Instruments:!SFJ36!!
No!significant!difference!between!preJ!and!postdiagnosis!
HRQOL!scores!was!apparent!for!any!age!group!or!any!stage!of!
disease.!!
No!
Korfage!(2006)! PCA! Pre!and!
post!
diagnosis!!
!
52!with!PCA!
Men;!67.3!(4.4),!
range!60J74;!
Rotterdam,!
Netherlands!
Registry!based!
participant!
identification!
Timepoints:!Before!
screening!and!median!31!
days!after!diagnosis!
Outcomes:!QoL!
Instruments:!SFJ36!
The!average!mental!health!and!selfJrating!of!own!overall!
health!scores!significantly!decreased!1!month!after!diagnosis!
Before!diagnosis:!SFJ36!Mental!health:!83.2!(12);!1!month!
After!diagnosis:!SFJ36!Mental!health:!75.8!(17)!
Yes!
Love!(2008)! PCA! Diagnosed!
vs.!
Comparison!
group.!
211!with!PCA! Men;!66.15!(8.26),!
43J92;!Victoria,!
Australia!
Recruited!from!
hospitals!
A!matched!group!of!
community!volunteers!
(n=169)!
Outcomes:!QoL,!
psychiatric!diagnoses,!
psychological!symptoms!
Instruments:!SFJ36,!CIDI!
for!DSMJIV,!BSIJ53!!
CIDI:!no!difference!in!depressive!disorders!but!increased!
prevalence!of!anxiety!disorders!(5.2%!vs.!3.6%).!
SFJ36:!RoleJemotional!was!lower!patients!than!controls:!PCA!
83.21!(21.85);!controls!88.49!(25.41),!the!other!3!scales!were!
similar!(vitality,!social!functioning,!mental!health).!BSI!scores!
did!not!differ!between!patients!and!controls.!
Yes,!
moderate!
Oba!(2014)! PCA! Pre!and!
post!
diagnosis!!
184!participants,!
99!with!PCA!
Men,!50s!J!80+!
(mean!68.8,!sd!6.5);!!
Japan/Gunma!
Patients!referred!for!
biopsy,!cancer!clinicJ
based!recruitment!
before!prostate!biopsy!
Time!points:!Before!
biopsy!and!1!month!after!
informed!of!diagnosis.!
Outcomes:!Distress,!
cancerJrelated!worry!
Instruments:!KJ6,!BCWI!
(each!item!is!on!a!scale!
0J100)!
KJ6:!No!difference!in!psychological!distress!before!biopsy!vs.!
after!diagnosis:!4.1!mean!(4.2!SD)!at!baseline,!4.5!mean!(4.6!
SD)!at!1!mo!after!diagnosis,!p=0.444.!!
No!
Perczek!(2002)! PCA! Pre!and!
post!
diagnosis!!
Of!the!101!who!
completed!
interviews,!37.6%!
(n!=38)!received!a!
diagnosis!!
Men;!66.7!(7.5),!46J
87;!Miami,!FL!and!
Palo!Alto,!CA!
Patients!scheduled!for!
a!prostate!biopsy!at!
the!urology!clinics.!
Timepoints:!Before!
diagnosis!and!2!weeks!
after!diagnosis.!
Outcomes:!Distress!
Instruments:!POMS!
Prebiopsy!POMS!distress!score:!Cancer:!0.61!(0.47).!
Postbiopsy!POMS!distress!score:!Cancer!0.79!(0.85).!
!
However,!cancer!status!was!not!a!significant!predictor!of!
increased!distress.!
Yes!
Wade!(2013)! PCA! Pre!and!
post!
diagnosis!
and!cancer!
vs.!
Comparison!
group!
1144!returned!
questionnaire!at!
biopsy,!!
405!
diagnosedwith!
PCA!
Men;!62.3!(5.2),!
range!50J59!
United!Kingdom!
Asymptomatic!men!in!
primary!care!
Comparison!Group:!
Negative!biopsy!
Timepoints:!
JT1:!initial!PSA!testing!
JT2:!before!biopsy!
JT3:!7!days!after!biopsy!
JT4:!35!days!after!biopsy!
(after!receipt!of!biopsy!
results)!
Outcomes:!Anxiety,!
depression!
Instruments:!HADS!
Anxiety:!clinical!cutoff!11!
HADS!Depression:!
clinical!cutoff!11!
T1:!
Cancer:!22!(6.0%)!had!anxiety!and!5!(1.4%)!!had!depression.!
No!cancer:!22!(5.4%)!had!anxiety!and!5!(1.2%)!!had!
depression.!
After!diagnosis!(T4):!
Cancer:!46!(12.9%)!had!anxiety!and!12!(3.4%)!!had!depression.!
No!cancer:!23!(5.6%)!had!anxiety!!and!9!(2.2%)!!had!
depression.!
Yes,!
moderate!
Results!reported!as!mean!(standard!deviation)!unless!otherwise!stated.!Abbreviations:!AAA,!abdominal!aortic!aneurysm;!PCA,!prostate!cancer;!WW,!watchful!waiting,!AS,!active!surveillance;!QoL,!quality!of!life;!STAI,!StateJTrait!Anxiety!
Inventory;!SFJ36,!The!Short!Form!(36)!Health!Survey;!MCS,!mental!component!summary;!HADS,!Hospital!Anxiety!and!Depression!Scale;!CIDI,!composite!international!diagnostic!interview,!DSMJIV,!Diagnostic!and!Statistical!Manual!of!
Mental!Disorders!4th!edition,!BSIJ53,!The!Brief!Symptom!Inventory;!KJ6,!!Kessler!psychological!distress!scale;!BCWI,!!Brief!CancerJrelated!Worry!Inventory;!POMS,!The!Profile!of!Mood!States!
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Table&2.&Descriptive&papers&on&AAA.&
First&Author&(Year)& Study&design& Number&of&
subjects&
Population&(Sex;&
age;&region)&
Type&of&sample&of&
subjects/Recruitment&
Time&of&
psychological&
assessment&
Outcomes& &
Instruments&
Main&results& Evidence&of&
psychological&
problems,&
frequency&
De!Rango!(2011)! RCT! 360!enrolled!/!
339!analyzed!
96%!men;!age!50J
79,!10!European!
centres!
Clinical.!10!European!clinical!
centres!
At!the!time!of!
enrollment!
(before!patients!
were!aware!of!the!
random!allocated!
treatment)!
Outcomes:!QoL!
Instruments:!SFJ
36!
Mean!values!for!total!group,!
before!randomization:!
Mental!component!
summary:!71.8!
Vitality:!67.9!
Social!functioning:!80.6!
Role!emotional:!80.3!
Mental!Health:!70.1!
(scores!not!interpreted)!
Uncertain!
Eisenstein!(2013)! RCT! 728!patients,!362!
received!
surveillance!/!350!
analyzed!
83.7%!male!in!
surveillance!
group,!median!
age!70!(25thJ75th!
percentiles!66.0J
76.0);!U.S.!
Clinical.!70!sites!J!The!
Cleveland!Clinic!coordinating!
center!managed!the!study.!
Within!3!months!
of!screening!
Outcomes:!QoL!
Instruments:!EQJ
5D!
Anxious!or!depressed:!
86/350!=!24.6%!
Utility!score:!0.783!(0.2)!!
VAS:!78.2!(15)!
Yes,!moderate!
Knops!(2014)! RCT! 178! 87%!men;!age!74!
(8)!and!72!(9)!in!
the!two!groups!
(decision!aid!and!
no!decision!aid);!
Netherlands!
Clinical.!Six!center,!
randomized!clinical!trial!in!
the!Netherlands!in!outpatient!
clinics!between!Nov!2008!and!
June!2011!
At!study!
enrollment!i.e.!
First!clinic!visit,!
before!treatment!
decision,!time!
since!diagnosis!
not!reported!
Outcomes:!
Anxiety!
Instruments:!
HADS!
Mean!anxiety!at!baseline:!
4.9!/!5.7!
(scores!not!interpreted)!
Uncertain!
Lederle!(2003)! RCT! 1136!participants,!
567!randomized!
to!imaging!
surveillance!
99%!men;!mean!
age!68;!U.S.!
Clinical.!Patients!were!
recruited!over!5!years!at!16!
Veterans!Affairs!medical!
centers!and!randomized!to!
immediate!open!surgical!
repair!or!surveillance.!!
Within!12!weeks!
of!diagnosis!
Outcomes:!QoL!
Instruments:!SFJ
36!
The!approximate!baseline!
men!values!can!be!!seen!
from!the!figures,!no!
interpretation.!
Mental!component!
summary:!52!
Vitality:!59!
Social!functioning:!85!
RoleJEmotional:!76!
Mental!Health:!75!
(scores!not!interpreted)!
Uncertain!
Results!reported!as!mean!(standard!deviation)!unless!otherwise!stated.!Abbreviations:!!AAA,!abdominal!aortic!aneurysm;!RCT,!randomized!controlled!trial;!QoL,!quality!of!life;!SFJ36,!The!Short!Form!(36)!
Health!Survey;!EQJ5D,!EuroQolJ!5!Dimension;!HADS,!Hospital!Anxiety!and!Depression!Scale!
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Table&3.&Descriptive&prostate&cancer&papers.&
First&Author&
(Year)&
Study&
design&
Number&of&
subjects&
Population&(Age;&
region)&
Type&of&sample&of&
subjects/Recruitment&
Time&of&
psychological&
assessment&
Outcomes& &Instruments& Main&results& Evidence&of&
psychological&
problems,&frequency&
Acar!(2024)! Cohort! 263!!with!AS!
initially!chosen!
/!
50!analyzed!
63.8!(6.9),!49–85;!
Amsterdam,!the!
Netherlands!
Clinical.!Selection!of!patients!
from!a!prospective!prostate!
cancer!database.!
Baseline!before!
treatment!
initiation!
Outcomes:!QoL!
Instruments:!EORTCJQLQJC30J
domain!15!
QoL!score!before!treatment:!83.00%!(SD!15.27)!
(scores!not!interpreted)!
Uncertain!
Bellardita!(2013)! Cohort! 154!enrolled!/!
103!analyzed!
67!(7),!!Milan,!Italy! Clinical.!Enrolled!via!clinic!if!
eligible!
At!study!entry! Outcomes:!QoL,!coping!with!
cancer!
Instruments:!FACTJP,!cutoff!for!
each!scale!is!3,!higher!is!better;!
MiniJMAC:!cutoff!2.5,!higher!is!
better!or!worse!or!depending!on!
item!!
FACTJP!(n=103):!emotional!wellJbeing!3.1;!28%!
under!cutJoff.!
MiniJMAC!(n=99):!helplessness/hopelessness!1.4!
(11%!above!cutJoff),!anxious!preoccupation!1.8!
(11%!above),!avoidance!2.4!(12%!above).!!
Yes,!high!
Berry!(2006)! CrossJ
sectional!
260! 63.2!(!8.1)!range!43J
83;!Puget!Sound!
region,!Washington!!
Clinical.!Invited!in!clinic!after!
diagnosis!at!3!treatment!
centers!+!men!with!PCA!who!
called!the!Cancer!Information!
Service!for!information!
At!the!time!of!of!
the!“options!talk”!J!
before!treatment!
decision!
Outcomes:!Anxiety!
Instruments:!STAI!
State!anxiety,!mean!32.7!(range!20J71),!Trait!
anxiety,!mean!31.19!(range!20J62)!
(scores!not!interpreted)!
Uncertain!
BillJAxelson!
(2013)!
RCT! 272!total,!136!
with!WW,!99!!
analyzed!
64.5!(4.7)!for!WW!
group!and!64.4!
(4.7)!for!RP!group;!
14!centers!in!
Sweden,!Finland,!
Iceland.!
Clinical.!MultiJcenter!trial.! Time!of!baseline!
questionnaire!
from!diagnosis!is!
not!reported.!
QuOutcomes:!QoL!
Instruments:!Questionnaire!
developed!by!the!authors!
Almost!all!men!reported!that!PCA!negatively!
influenced!daily!activities!and!relationships.!
HealthJrelated!distress,!worry,!feeling!low,!and!
insomnia!were!consistently!reported!by!
approximately!30J40%.!
Yes,!high!
Bisson!(2002)! CrossJ
sectional!
88! 64.5!(6.7,!48–78);!!
Wales!UK!
Clinical.!Patients!were!
consecutive!referrals!with!a!
new!diagnosis!of!clinically!
localized!prostate!cancer!to!a!
clinic!
Before!first!clinic!
appointment.!
"Newly!diagnosed!
patients".!
Outcomes:!QoL,!distress,!anxiety,!
depression,!psychological!
response!to!diagnosis!
Instruments:!SFJ36,!GHQ30,!
HADS,!!IESJR,!!EORTCJQLQJC30!
GHQJ30!3.24!(4.95)![0–25]!25%!and!9%!above!
the!two!cutJoffs;!HADSJA!4.96!(3.82)![0–16]!22%!
or!10%!!above!the!two!cutJoffs;!HADSJD!1.95!
(2.5)![0–10]!5%!or!0%!!above!the!two!cutJoffs,!
IESR:!14%!above!cutoff!on!intrusion!and!
avoidance;!QoL!Emotional!functioning!1.54!
(0.69),!scale!1J4.!
Yes,!moderate!
Chambers!(2014)! Cohort! 740!(Study!1)! 63.4!(7.5),!range!
43.3J83.6;!South!
East!and!North!
Queensland,!
Australia!
Clinical.!Men!were!referred!
to!the!project!by!their!
urologists!if!they!had!
localized!prostate!cancer!
suitable!for!treatment!with!
curative!intent.!
Median!time!since!
diagnosis!19!days;!
mean!25.6!days!
(SD!26.9)!!
Outcomes:!Distress!
Instruments:!DT,!scale!0J10;!IESJR:!
a!cutJoff!of!>33!out!of!a!total!
possible!score!of!88!indicates!high!
distress!
Study!1:!
DT!mean!3.1!!SD!2.5!
IESJR!(cutoff!>=34):!10%!distressed!
!!
Yes,!moderate!
Chhatre!(2011)! Cohort! 198! 64.1!(8.6)!and!63.0!
(7.9)!for!white!and!
black,!respectively;!
Philadelphia,!PA!
Clinical.!Urology!clinics!of!
urban!healthcare!system!and!
VA!Medical!Center!
Within!4!months!
of!diagnosis!
Outcomes:!QoL!
Instruments:!!FACTJP!
White:!FACTJP!total!score:!123.7!(23.7)!
Emotional!wellJbeing:!19.2!(4.1)!
Black:!FACTJP!total!score:!117.1!(26.4)!
Emotional!wellJbeing:!19.3!(3.7)!
(scores!not!interpreted)!
Uncertain!
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Couper!(2009)! Cohort! 211!recruited;!
193!completed!
the!baseline!
questionnaire,!
61!chose!WW!
Mean!age!66.15!
(range!43J92);!
Melbourne,!
Australia!
Clinical.!Recruitment!by!
urologists!and!oncologistsJ
PCA!pts!attending!clinics!in!
public!hospitals!and!private!
practices.!
Close!to!initial!
diagnosis!and!
close!to!
commencement!of!
definitive!
treatment!
Outcomes:!Depression!and!
anxiety,!QoL!
Instruments:!Brief!Symptom!
Inventory,!SFJ36!
WW!group!only:!!
Depression:!0.147!(0.4),!Anxiety:!0.246!(0.3)!
SF36:!Vitality:!75.08!(15.5),!Social!Functioning:!
89.14!(16.0),!RoleJemotional:!87.43!(28.6),!
Mental!health:!80.59!(16.5).!
(scores!not!interpreted)!
Uncertain!
Jayadevappa!
(2012)!
Cohort! 214!enrolled!/!
195!analyzed!
69.87!(4.5)!and!
71.25!(4.1)!for!
white!and!black,!
respectively;!
Philidelphia,!PA!
Clinical.!Urban!academic!
hospital!and!a!VA!hospital!!
Caucasian!vs.!AA.!!
Timepoints:!
baseline,!3,!6,!12!
months!
Outcomes:!QoL!
Instruments:!SFJ36!
Baseline!mental!health!score:!Caucasian!
81.8±14.3,!AA!75.8±14.3!
(scores!not!interpreted)!
Uncertain!
Jayadevappa!
(2012)!
Cohort! 602!at!baseline! 63.3!(8.0);!
Pennsylvania!
Clinical.!Urban!academic!
hospital!and!a!VA!hospital!!
Baseline!before!
treatment!
initiation!
Outcomes:!QoL!
Instruments:!SFJ36!
Baseline!SFJ36!mental!health!mean!76.4!(18.2).!!
(scores!not!interpreted)!
Uncertain!
Loiselle!(2010)! Cohort! 45! 62.3!(7.7)!and!67.7!
(9.6)!for!the!two!
groups;!Quebec,!
Canada!
Clinical.!Convenience!sample!
recruited!from!four!oncology!
ambulatory!clinics!and!large!
teaching!hospitals!
At!enrollment! Outcomes:!Anxiety,!QoL!
Instruments:!STAI,!SFJ36!
Depression!15.8!(4.6)!and!19.8!(8.3)!!
Anxiety!30.1!(11.7)!and!36.1!(13.0)!
Mental!QoL!58.7!(8.7)!and!53.0!(11.0)!
(scores!not!interpreted)!
Uncertain!
Mohamed!(2012)! Cohort! 986!enrolled!/!
869!analyzed!!
65.45!(7.57),!39!J!83!
years;!Northeast!of!
the!US!
Clinical.!Patients,!tertiary!
cancer!center;!patients!
entering!treatment.!!
Within!4!to!6!
weeks!of!diagnosis!
Outcomes:!Depression!
Instruments:!CESJD,!cutJoff!score!
9!indicating!elevated!depressive!
symptoms!
Mean!CESJD!score!5.11!(SD!4!.42;!range!0!–27).!A!
fifth!of!the!sample!(19.7%)!reported!clinically!
elevated!levels!of!depressive!symptoms!at!
baseline.!
Yes,!moderate!
Mohan!(2009)! CrossJ
sectional!
184!total;!23!
(12.5%)!patients!
chose!WW.!
68.2!(5.9);!Norfolk,!
Virginia.!
Clinical.!All!patients!were!
recruited!from!a!large,!
private!urology!practice.!
Baseline!within!6!
months!of!
diagnosis!!
Outcomes:!Depression!and!
anxiety,!life!satisfaction!
Instruments:!SFJ36,!HADS,!Life!
satisfaction!scale!
SFJ36!(n=8):!MCS!46.4!(4.5)!!
HADS!(n=23):!Anxiety:!2.8!(2.9),!only!1!had!
moderate!anxiety!(11J14)!(4%),!other!22!had!
normal!scores!(0J7).!Depression:!1.4!(1.7),!all!had!
normal!scores!(0J1,!none/normal).!
Life!satisfaction!(n=22):!6.1(1.0),!17!(77.3%)!were!
delighted!or!highly!satisfied,!5!(22.7%)!satisfied!
or!lower.!!
Yes,!low!
Punnen!(2013)! Cohort! 679!total,!122!
chose!AS!
60.1!(6.7)!for!all,!
60.5!(6.5)!for!AS;!
Department!of!
Urology!at!The!
University!of!
California,!San!
Francisco!(UCSF)!
Clinical.!Prospective!cohort!of!
newly!diagnosed!patients.!
Before!initial!clinic!
visit,!not!specified!
how!soon!after!
diagnosis!
Outcomes:!Depression,!anxiety,!
distress!
Instruments:!PHQJ9:!CutJoffs!of!5,!
10,!15!and!20!correspond!to!mild,!
moderate,!moderately!severe,!
and!severe!depression.!GADJ7:!
CutJoffs!of!5,!10!and!15!
correspond!to!mild,!moderate!and!
severe!anxiety.!DT:!Scores!≥4!
indicating!elevated!distress.!
Baseline!prevalence!of!moderate!or!higher!levels!
of!depression!or!anxiety!were!low!(<5%),!while!
levels!of!mild!depression!or!anxiety!ranged!from!
3–16%!over!time.!Baseline!levels!of!elevated!
distress!ranged!from!8–20%.!AS!group:!
Depression:!11%!mild,!3%!moderate,!1%!
moderately!severe.!Anxiety:!14%!mild,!2%!
moderate,!1%!severe.!Distress:!Elevated!20%.!
Yes,!moderate!
Selli!(2014)! Cohort! 672!enrolled,!!
603!analyzed!
Mean!65.0!(5.73),!
median!66.0!(range!
50–75)!!
PanJEuropean!
(Germany,!France,!
Spain,!Italy,!
Sweden)!
Clinical.!This!was!a!
prospective,!1Jyear,!
observational,!panJEuropean!
study!of!men!with!prostate!
cancer!of!lowJtoJmoderate!
risk!of!progression!
All!questionnaires!
were!completed!at!
baseline!(within!2!
months!of!
diagnosis!and!
before!treatment)!
Outcomes:!QoL,!anxiety,!
depression!
Instruments:!EORTC!QLQJC30,!EQJ
5D,!HADS!
QLQJC30:!Emotional!functioning!scale!(n=396)!
80.1!(3.88).!Compared!with!ageJ!matched!
normative!data!(UK!general!population),!anxiety!
was!significantly!lower!(<!0.001)!in!the!study!
population,!while!depression!was!similar.!
No!
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Siston!(2003)! Cohort! Of!the!enrolled!
patients!(n!=!
140),!70%!(n!=!
98)!had!
localized!
disease,!39!
chose!WW!
Mean!69,!range!47–
84;!United!States!
Clinical.!All!patients!with!
newly!diagnosed!PCa!who!
met!the!eligibility!criteria!at!
five!VA!Medical!Centers!
across!the!United!States!
Median!time!from!
diagnosis!was!1.2!
months,!with!85%!
enrolled!within!2!
months!of!
diagnosis.!
Outcomes:!QoL!
Instruments:!EORTCJQLQJC30+3!
EORCT!QL!is!reported!at!baseline!separately!for!
groups.!WW!(HRQL!global!69.5,!emotional!QL!
83.5),!RP!(global!68.0,!emotional!76.1),!and!RT!
(global!70.9,!emotional!81.4).!!
(scores!not!interpreted)!
Uncertain!
Soloway!(2005)! CrossJ
sectional!
103! Mean!62,!median!
(range)!62!(43–80);!
Miami,!Florida,!US.!
Clinical.!Following!methods!of!
convenience!sampling,!
consecutive!untreated!
referrals!were!identified!in!
the!academic!outpatient!
setting.!
85%!of!the!
patients!had!been!
diagnosed!within!
the!last!3!months.!!
Outcomes:!Depression,!distress!
Instruments:!BDI,!POMS,!VAS!of!
distress!
Frequency!of!depression!according!to!BDI!
cutoffs:!!mildJmoderate!19.2%;!moderateJ
severe,!2%;!and!severe!0%.!The!mean!BDI!score!
(5.63)!and!mean!POMS!total!mood!disturbance!
score!(51.52)!were!within!normal!range.!
Yes,!moderate!
Steginga!(2004)! Cohort! 111! 61.5!(8.1).!
Queensland,!
Australia.!
Clinical.!The!participants!
were!men!newly!diagnosed!
with!localized!prostate!cancer!
recruited!from!two!hospital!
urology!clinics!and!four!
urologists’!private!practices!
Time!since!
diagnosis!4.3!(4.6)!
weeks.!
Outcomes:!Psychological!response!
to!diagnosis,!life!satisfaction!
Instruments:!IESJR,!Constructed!
Meaning!Scale,!Satisfaction!with!
Life!Scale.!!
Pooled!data!for!all!treatment!groups!before!
treatment:!24%!had!high!and!41%!had!moderate!
levels!of!avoidance,!16%!had!high!and!43%!had!
moderate!levels!of!intrusion.!Satisfaction!with!
life!26.3!(6.3)!was!similar!to!norms!reported!for!
community!samples.!Constructed!meaning!24.1!
(4.0),!no!interpretation.!
Yes,!high!
Torvinen!(2013)! CrossJ
sectional!
!630!total,!47!
had!localized!
disease!!
68.5!(8.2),!range!44J
93;!
Southern!Finland!
Clinical.!Recently!diagnosed!
patients!were!enrolled!when!
visiting!the!hospital.!!
Within!6!months!
of!diagnosis!(mean!
time!1.7!months)!
Outcomes:!QoL!
Instruments:!15D,!and!EQJ5D,!
EORTC!QLQJC30!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
15D:!mean!0.91!(0.09),!95%!CI!(0.89J0.94)!!
EQJ5D:!mean!0.90!(0.19),!95%!CI!(0.84J0.96)!!
VAS:!mean!81.11!(14.87),!95%!CI!(76.69J85.52)!!!!!!!!!!!!!!!!!!!!
QLQJC30:!mean!81!
15D!(dimensions!of!speech,!mental!function,!and!
discomfort!and!symptoms)!and!EQJ5D!gave!
higher!scores!than!those!of!the!general!
population.!
No!
van!den!Bergh!
(2009)!
CrossJ
sectional!
129! 64.9!(6.89);!the!
Netherlands!
Clinical.!Between!May!2007!
and!May!2008,!all!Dutch!men!
(N!=!150)!who!had!a!recent!
(<6!months)!diagnosis!of!PCA!
and!who!were!included!in!the!
PRIAS!study!received!a!QoL!
questionnaire!at!their!home!
address.!!
Within!6!months!
of!diagnosis,!mean!
2.7!months!(SD!
1.7)!and!median!
2.4!months!(>50%!
were!within!3!
months!of!
diagnosis)!
Outcomes:!Depression,!anxiety,!
QoL!
Instruments:!CESJD:!clinical!
threshold!16,!STAIJ6:!clinical!
threshold!44,!MAXJPC!(PCAJ
specific!anxiety):!clinical!threshold!
27,!SFJ12!MCS!
Mean/median,!SD;!Frequency!n!(%)!scoring!
above!clinical!cutoff:!
CESJD:!5.7/4,!6.1;!Freq!10!(8%)!
STAIJ6:!35.9/35,!9.0;!Freq!22!(17%)!
MAXJPC:!13.9/14,!8.8!
!!!PC!anxiety!9.3/8,!6.8;!Freq!9!(7%)!
!!!PSA!anxiety!0.3/0,!1!!
!!!Fear!of!recurrence:!4.3/4,!2.5!
SFJ12!MCS!score!50.3/54.3,!9.4!
Yes,!moderate!
Vasarainen!(2012)! Cohort! 124!patients,!
105!returned!
baseline!
questionnaire!
Median!64,!range!
55J74;!!
Finland!
Clinical.!Recruitment!
according!to!the!PRIAS!
protocol.!
At!the!start!of!
surveillance!
Outcomes:!QoL!
Instruments:!SFJ36!
SFJ36:!
RoleJemotional:!82!(32.6)!
Mental!health:!81!(14.9)!
Social!function:!91!(14.4)!
Vitality:!76!(15.7)!
Compared!with!the!Finnish!male!population,!
both!mental!and!physical!HRQL!scores!of!the!
PRIAS!patients!were!significantly!better.!
No!
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Results!reported!as!mean!(standard!deviation)!unless!otherwise!stated.!Abbreviations:!PCA,!prostate!cancer;!WW,!watchful!waiting,!AS,!active!surveillance;!RCT,!randomized!controlled!trial;!QoL,!quality!of!life;!!HRQL,!healthJ
related!quality!of!life,!EORTC!QLQJC30,!European!Organization!for!Research!and!Treatment!of!Cancer!Quality!of!Life!QuestionnaireJCancer!30;!FACTJP,!Functional!Assessment!of!Cancer!Therapy!Prostate!version;!MiniJMAC,!MiniJ
Mental!Adjustment!to!Cancer;!STAI,!StateJTrait!Anxiety!Inventory;!SFJ36,!The!Short!Form!(36)!Health!Survey;!MCS,!mental!component!summary;!GHQ30,!the!30JItem!General!Health!Questionnaire;!HADS,!Hospital!Anxiety!and!
Depression!Scale;!IESJR,!the!Impact!of!Event!ScaleJRevised;!DT,!Distress!Thermometer;!15D,!15!Dimensions!index;!CESJD,!Center!for!Epidemiological!Studies!Depression!scale;!!Patient!Health!Questionnaire!(PHQJ9);!GADJ7,!
General!Anxiety!Disorder!scale!7;!VAS,!Visual!analogue!scale;!EQJ5D,!EuroQolJ!5!Dimension;!BDI,!Beck!Depression!Inventory,!POMS,!The!Profile!of!Mood!States;!MAXJPC,!Memorial!Anxiety!Scale!for!Prostate!Cancer!!
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Table&4.&Qualitative&studies&on&AAA&and&prostate&cancer&
First&author&(Year)& Number&of&
subjects&
Psychological&measures&used& Main&findings& Evidence&of&&
psychological&
problems&(yes&/&no)&
Cayless!(2009)! 10! Open!!inJdepth!interviews!! Initial!shock!and!surprise,!worry!about!the!treatment,!bracketing!the!experience!of!cancer!as!
a!separate!entity!splitJoff!from!oneself,!feeling!of!being!“back!to!normal”!after!going!through!
the!treatment!(as!compared!to!the!time!of!diagnosis).!
Yes!
Gunasekera!(2014)! 6! Focus!session!conducted!by!three!
researchers!with!audio!recording!
and!transcribed!verbatim.!
Transcripts!were!then!reviewed!by!3!
researchers.!Framework!analysis!was!
used!to!analyze!and!record!data.!!!
“There!was!a!consensus!among!participants!that!the!diagnosis!of!an!AAA!had!come!as!a!
surprise,!and!one!participant!noted!it!was!like!a!‘‘shot!out!of!the!blue.’’!Participants!
commented!that!the!shock!of!diagnosis!was!also!accompanied!by!a!sense!of!not!knowing!
what!to!expect:!‘‘I!was!really!in!the!dark!and!wondering!what!would!happen!next.’’!There!
was!also!a!concern!for!the!future!and!a!sense!of!hopelessness!in!terms!of!being!able!to!
manage!their!condition.”!
Yes!
Hansson!(2012)! 15! Semi!structured!interview! Majority!of!men!worried!to!a!greater!or!lesser!extent!about!their!diagnosis.!Some!but!not!all!
felt!calmer!after!talking!to!a!doctor.!Overall,!people!expressed!feeling!of!worry,!anxiety,!and!
existential!thoughts!about!the!fragility!and!finiteness!of!life.!Some!did!express!appreciation!
for!having!the!knowledge!of!diagnosis.!!
Yes!
Pettersson!(2013)! 10! Dialogue!without!the!use!of!
interview!guide!
Most!of!the!conditions!were!diagnosed!when!looking!at!something!and!were!sudden!to!
patients.!They!“felt!afflicted!by!a!lifeJthreatening!condition,!entailing!inevitability,!great!
concern,!guilt,!and!many!questions”;!“After!detection!and!awareness!of!the!aneurysm,!any!
physical!symptom!especially!in!the!abdomen!caused!concern,!which!had!an!adverse!impact!
on!daily!life”!
Yes!
Ervik!(2010)! 10! InJdepth!interviews! Getting!the!diagnosis!was!an!overwhelming!experience,!and!daily!life!with!the!illness!caused!
anxiety,!uncertainty,!and!a!feeling!of!being!alone.!The!men!were!thrown!into!a!new!situation!
that!they!were!unprepared!for,!and!they!expressed!worries!about!treatment,!prognosis,!and!
the!future.!!
Yes!
Kronenwetter!(2005)! 26! InJdepth!semistructured!interviews! The!cancer!diagnosis!was!met!with!anxiety,!distress,!and!denial,!or!a!“bump!in!the!road”!
attitude.!!
Yes!
Wall!(2013)! 8! InJdepth!semistructured!interviews! After!an!initial!feeling!of!shock,!the!men!tried!to!camouflage!their!experience!of!distress!
through!hiding!and!attenuating!their!feelings.!
Yes!
Wallace!(2007)! 17! Focus!groups! Feelings!at!receiving!the!diagnosis:!shock,!blindsided,!body!blow,!fear,!anger,!roller!coaster;!
"the!word!cancer!is!followed!closely!in!my!mind!with!death";!"I!had!to!stay!away!from!the!
world";!surprise,!"It!was!the!last!thing!in!the!world!I!thought!I!would!have,"!"I!didn't!even!
know!what!the!prostate!was"!
Yes!
 DISCUSSION 
Our systematic review examined psychological effects of receiving a diagnosis of one of 
two conditions: AAA and localized prostate cancer. Eight papers on AAA and 32 papers 
on PCA were included in this review; these 40 papers were also subdivided into 32 
quantitative and eight qualitative studies. Registry studies were not included in this 
analysis. Approximately half of the quantitative studies demonstrated at least some 
psychological distress during the early post-diagnosis period that may be associated 
with labeling.  Despite a small number of patients in qualitative papers, all eight 
identified at least some psychological problems in patients after receiving a diagnosis.  
 
Whether studies found possible harms of diagnostic labeling depended on study type, 
study design, and the measures used. The manner in which the authors reported their 
results also contributed to whether presence of psychological problems could be 
evaluated. Quantitative studies using general quality of life measures such as the SF-36 
and reporting only mean values for the study populations found few psychological 
problems. In contrast, qualitative studies using individual in-depth interviews were able 
to uncover psychological distress experienced by the subjects. We propose three 
possible explanations to this disagreement.  
 
First, the general quantitative measures used in most studies may not have been 
sensitive enough to detect the type of psychological distress caused by diagnostic 
labeling. An individual distressed by labeling may be able to function normally in day-to-
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day life and not be clinically depressed but still experience fear, worry, and other forms 
of psychological suffering. Even low-grade distress, if experienced by a large number of 
people, may add to substantial distress from screening for a population.   
 
Secondly, the lack of an appropriate control group in the majority of studies makes it 
difficult to interpret the level of psychological distress that the studies document.  It also 
makes us uncertain as to whether we can attribute the psychological distress that was 
found to labeling.  These findings can only be suggestive rather than definitive.  Most 
helpful in the future would be studies that compare the psychological status of 
individuals before and after diagnosis with similar measures in untested individuals in 
the general population, as study participants are often a selected group that may differ 
from the general population in a multitude of ways. Notably, all studies with a control 
group found at least some indication of more psychological problems among those who 
received a diagnosis as compared to those who did not. Only one study used matched 
community volunteers as control group. They found more anxiety disorders among the 
diagnosed individuals than among control subjects, suggesting psychological harm 
caused by diagnostic labeling. 
 
Third, few studies measured psychological distress or quality of life before diagnosis, 
and only two studies measured psychological state before screening. Therefore, for the 
majority of studies, we were unable to evaluate whether a decline in wellbeing was 
experienced by the individuals after they received the diagnosis. Of studies evaluating 
psychological state before and after diagnosis, both studies that measured 
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psychological state before screening and after diagnosis showed an increase in 
distress, whereas results of studies comparing psychological state before and after the 
prostate biopsy were more mixed. This may be due to increased psychological distress 
following a positive screening result, already before the diagnosis is confirmed.  
 
In addition to issues already discussed above, the analysis presented in this masters 
paper was limited in several ways. In many of the reviewed studies it was unclear 
whether participants had already decided on treatment modality at the time of 
psychological assessment. The decision process itself as well as the anticipation of 
treatment may have influenced the psychological state of some patients. The time from 
diagnosis to psychological assessment varied both across and within studies, and in 
many cases the exact time since diagnosis was not reported. These discrepancies may 
explain some of the differences between studies, as the initial psychological reaction to 
a diagnosis may be very different from what the individual is experiencing weeks or 
months later. In observational studies, those selecting watchful waiting or active 
surveillance may differ favorably in terms of psychological traits from those who choose 
active treatments, which may have led to underestimation of the psychological effects of 
labeling in studies focusing on this patient group only. In some studies, particularly 
protocol-defined trials, individuals were excluded if they had a history of mental illness. 
This may reduce generalizability of the results to real populations, where those with a 
history of psychiatric disorders may be particularly susceptible to the negative 
psychological effects of labeling. Similarly, the generalizability may suffer from the fact 
that many studies were conducted in university hospitals or other specialized treatment 
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centers, the patient population of which may differ from primary care or community 
settings. 
 
Implications for research 
The lack of appropriate control groups and pre-screening psychological measures in the 
majority of the reviewed studies reflect the fact that very few studies were specifically 
designed to assess the psychological effects of receiving a diagnosis. In fact, none of 
the studies actually mentioned the term “labeling”.  Our findings suggest that diagnostic 
labeling is a real phenomenon that merits further study and efforts should be made to 
better conceptualize the meaning of labeling and to develop measures that can detect 
both the frequency and severity of the type of distress that it causes.  Care should also 
be taken in the design of studies to assess labeling. One issue, for example, is the 
nature of the comparison group. The ideal comparison group would be the 
counterfactual: how would the same individuals fare had they not received the 
diagnosis. But even the act of screening may cause distress, so the optimal comparison 
group would be people not considering screening at all. An additional issue is the need 
to examine change in distress levels before and after diagnosis, rather than distress 
only after diagnosis.  Thus, pre-screening measures should be contrasted to post-
diagnosis measures. Further, the instruments used to measure distress should be 
sensitive enough to detect psychological problems less severe than pathological 
depression and anxiety. Condition-specific measures may be preferable to general 
ones, and it may be necessary to develop new instruments to more accurately evaluate 
the effects of diagnostic labeling on psychological wellbeing. 
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Much needs to be learned about the phenomenon of labeling:  
- what types of people are most affected? 
- what types of conditions does the diagnosis create higher levels of distress?  
- what happens to levels of labeling distress over time? 
Studies should be designed specifically to answer these questions. 
 
Implications for public health 
Screening is a popular method for preventing morbidity and mortality from certain 
conditions in the population, as it enables early detection and intervention. This review 
provides a systematic review of the evidence of psychological problems among 
individuals receiving a diagnosis of a condition they were unaware of. This is particularly 
problematic for conditions that remain asymptomatic for a long period of time and may 
never even progress to symptomatic conditions. The results of this review highlight the 
importance of considering the possible adverse effects of diagnostic labeling when 
planning screening programs and when making guidelines for screening in primary care 
settings. If large populations are subjected to screening, even relatively low levels of 
harm experienced by the individuals can cause a considerable burden of suffering in the 
population. Similarly, if new screening programs are introduced or existing programs are 
extended to new population segments, the absolute number of people experiencing 
harms will also increase, and may outweigh – on a population basis – the few who may 
benefit.  
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Conclusion 
The results of this systematic review suggest that diagnostic labeling may cause 
psychological harm. This may cause a considerable burden of suffering in the 
population following large-scale screening programs. Yet, due to the lack of metrics 
specific for measuring these harms and the paucity of studies aimed specifically at 
studying the effects of diagnostic labeling, these results must be viewed as an initial 
attempt to address this question. Future studies should evaluate what instruments are 
best suited for measuring the psychological effects of diagnostic labeling and how to 
quantify these effects in populations offered screening.  
 
Perhaps most importantly, the issue of labeling needs to be acknowledged. Since the 
initial studies of this problem some 40 years ago, few studies have examined this 
potential harm.  Thus, the term labeling is not well defined and not well measured.  With 
the increasing use of the term overdiagnosis, which would include the dual harms of 
labeling and overtreatment, researchers, guideline developers, clinicians, and patients 
should all factor the potential harm of labeling into decisions about screening.  
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APPENDIX 
 
Appendix A. Prostate Cancer Labeling Review Search  
 
PubMed 
23MAR2015 
Found 3918 
 
(Prostate cancer*[tw] OR prostatic cancer*[tw] OR Prostatic Neoplasms[Mesh] OR prostate specific 
antigen[tw] OR PSA[tw]) AND (screening*[tw] OR diagnos*[tw] OR early diagnosis[tw] OR early 
detection[tw] OR biops*[tw] OR surveillance[tw] OR watchful waiting[tw] OR overdiagnos*[tw] OR 
over diagnos*[tw] OR overdetect*[tw] OR over detect*[tw] OR insignifican*[tw]) AND (depress*[tw] 
OR distress[tw] OR stress*[tw] OR worry[tw] OR fear*[tw] OR anxiet*[tw] OR quality of life[tw] OR 
mental health[tw] OR mental disorders[tw] OR psycholog*[tw] OR psychosocial[tw] OR wellbeing[tw] 
OR well-being[tw] OR emotion*[tw] OR false positive*[tw] OR stigma[tw] OR shame[tw] OR 
label*[tw] OR suicid*[tw]) 
 
Limits: Publication Dates From 2002/01/01 to 2014/12/31 
 
CINAHL via EBSCO 
23MAR2015 
Found 354 
 
Search 
(MH "Prostatic Neoplasm*" OR “Prostate cancer*” OR “prostatic cancer*” OR “prostate specific 
antigen” OR PSA) 
AND (screening* OR diagnos*[tw] OR “early diagnosis” OR “early detection” OR biops* OR 
surveillance OR “watchful waiting” OR overdiagnos* OR “over diagnos*” OR overdetect* OR “over 
detect*” OR insignifican*) 
AND (depress* OR distress OR stress* OR worry OR fear* OR anxiet* OR “quality of life” OR “mental 
health” OR “mental disorders” OR psycholog* OR psychosocial OR “well being” OR emotion* OR 
“false positive*” OR stigma OR shame OR label* OR suicid*) 
 
Limits: Publication Date from 2002/01/01-2014/12/31 
 
PsycINFO via EBSCO 
23MAR2015 
Found 326 
 
("Prostatic Neoplasm*" OR “Prostate cancer*” OR “prostatic cancer*” OR “prostate specific antigen” OR 
PSA) 
AND (screening* OR “early diagnosis” OR “early detection” OR biops* OR surveillance OR “watchful 
waiting” OR overdiagnos* OR “over diagnos*” OR overdetect* OR “over detect*” OR insignifican*) 
AND (depress* OR distress OR stress* OR worry OR fear* OR anxiet* OR “quality of life” OR “mental 
health” OR “mental disorders” OR psycholog* OR psychosocial OR “well being” OR emotion* OR 
“false positive*” OR stigma OR shame OR label* OR suicid*) 
Limits: Publication Date from 2002/01/01-2013/12/31  
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Appendix B. Prostate Cancer Labeling Review Bridge Search  
 
PubMed 
10SEP2015 
Found 309 
 
(Prostate cancer*[tw] OR prostatic cancer*[tw] OR Prostatic Neoplasms[Mesh] OR prostate specific 
antigen[tw] OR PSA[tw]) AND (screening*[tw] OR diagnos*[tw] OR early diagnosis[tw] OR early 
detection[tw] OR biops*[tw] OR surveillance[tw] OR watchful waiting[tw] OR overdiagnos*[tw] OR 
over diagnos*[tw] OR overdetect*[tw] OR over detect*[tw] OR insignifican*[tw]) AND (depress*[tw] 
OR distress[tw] OR stress*[tw] OR worry[tw] OR fear*[tw] OR anxiet*[tw] OR quality of life[tw] OR 
mental health[tw] OR mental disorders[tw] OR psycholog*[tw] OR psychosocial[tw] OR wellbeing[tw] 
OR well-being[tw] OR emotion*[tw] OR false positive*[tw] OR stigma[tw] OR shame[tw] OR 
label*[tw] OR suicid*[tw]) 
 
Limits: Publication Dates From 2015/01/01 to 2015/08/31 
 
CINAHL via EBSCO 
10SEP2015 
Found 31 
 
Search 
(MH "Prostatic Neoplasm*" OR “Prostate cancer*” OR “prostatic cancer*” OR “prostate specific 
antigen” OR PSA) 
AND (screening* OR diagnos*[tw] OR “early diagnosis” OR “early detection” OR biops* OR 
surveillance OR “watchful waiting” OR overdiagnos* OR “over diagnos*” OR overdetect* OR “over 
detect*” OR insignifican*) 
AND (depress* OR distress OR stress* OR worry OR fear* OR anxiet* OR “quality of life” OR “mental 
health” OR “mental disorders” OR psycholog* OR psychosocial OR “well being” OR emotion* OR 
“false positive*” OR stigma OR shame OR label* OR suicid*) 
 
Limits: Publication Date from 2015/01/01 to 2015/08/31 
 
PsycINFO via EBSCO 
10SEP2015 
Found 10 
 
("Prostatic Neoplasm*" OR “Prostate cancer*” OR “prostatic cancer*” OR “prostate specific antigen” OR 
PSA) 
AND (screening* OR “early diagnosis” OR “early detection” OR biops* OR surveillance OR “watchful 
waiting” OR overdiagnos* OR “over diagnos*” OR overdetect* OR “over detect*” OR insignifican*) 
AND (depress* OR distress OR stress* OR worry OR fear* OR anxiet* OR “quality of life” OR “mental 
health” OR “mental disorders” OR psycholog* OR psychosocial OR “well being” OR emotion* OR 
“false positive*” OR stigma OR shame OR label* OR suicid*) 
 
Limits: Publication Date from 2015/01/01 to 2015/08/31 
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Appendix C. Abdominal Aortic Aneurysm Labeling Review Search  
 
PubMed 
10SEP2015 
Found 255 
 
(Abdominal aortic aneurysm[tw] OR Aortic Aneurysm, Abdominal[Mesh]) AND (screening*[tw] OR 
diagnos*[tw] OR early diagnosis[tw] OR early detection[tw] OR biops*[tw] OR surveillance[tw] OR 
watchful waiting[tw] OR overdiagnos*[tw] OR over diagnos*[tw] OR overdetect*[tw] OR over 
detect*[tw] OR insignifican*[tw]) AND (depress*[tw] OR distress[tw] OR stress*[tw] OR worry[tw] OR 
fear*[tw] OR anxiet*[tw] OR quality of life[tw] OR mental health[tw] OR mental disorders[tw] OR 
psycholog*[tw] OR psychosocial[tw] OR well being[tw] OR false positive*[tw] OR emotion*[tw] OR 
stigma[tw] OR shame[tw] OR label*[tw] OR suicid*[tw]) 
 
Limits: Publication Dates From 2002/01/01 to 2015/08/31 
 
CINAHL via EBSCO 
10SEP2015 
Found 40  
 
Search 
(MH "Aortic Aneurysm, Abdominal” OR “abdominal aortic aneurysm*”) 
AND (screening* OR diagnos*[tw] OR “early diagnosis” OR “early detection” OR biops* OR 
surveillance OR “watchful waiting” OR overdiagnos* OR “over diagnos*” OR overdetect* OR “over 
detect*” OR insignifican*) 
AND (depress* OR distress OR stress* OR worry OR fear* OR anxiet* OR “quality of life” OR “mental 
health” OR “mental disorders” OR psycholog* OR psychosocial OR “well being” OR emotion* OR 
“false positive*” OR stigma OR shame OR label* OR suicid*) 
 
Limits: Publication Date from 2002/01/01 to 2015/08/31 
 
 
PsycINFO via EBSCO 
10SEP2015 
Found 13 
 
("Aortic Aneurysm, Abdominal” OR “abdominal aortic aneurysm*”) 
AND (screening* OR diagnos*[tw] OR “early diagnosis” OR “early detection” OR biops* OR 
surveillance OR “watchful waiting” OR overdiagnos* OR “over diagnos*” OR overdetect* OR “over 
detect*” OR insignifican*) 
AND (depress* OR distress OR stress* OR worry OR fear* OR anxiet* OR “quality of life” OR “mental 
health” OR “mental disorders” OR psycholog* OR psychosocial OR “well being” OR emotion* OR 
“false positive*” OR stigma OR shame OR label* OR suicid*) 
 
Limits: Publication Date from 2002/01/01 to 2015/08/31 
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Appendix D.  Harms of Labeling Systematic Review Inclusion and Exclusion Criteria 
 
1. Exclusion/Inclusion criteria  
a. Include  
i. Subjects given a diagnosis of one of our 2 conditions (AAA; prostate cancer) 
ii. Outcome is frequency or burden of a psychological state, with first measure 
within 3 months of diagnosis, average measurement ≤6 months of diagnosis. 
1. Active surveillance/watchful waiting studies 
2. Results reported as (for example) 
a. Means and SDs 
b. Proportion of subjects with scores above/below a cut-off 
c. Mild, moderate, severe states 
d. Rates (e.g., of suicide) 
e. Subjects’ subjective description (qualitative interviews or focus 
groups) 
iii. Subjects diagnosed via screening and work-up, not because of symptoms 
iv. Include registry-based data on suicide, psych med prescription or hospitalization, 
etc. 
1. These studies will not generally specify if subjects were diagnosed by 
screening or because of symptoms, but include nonetheless  
v. Not necessary (although desirable) to have a comparison group 
1. Qualitative studies generally will not have one 
2. Large studies may use population norms or rates 
3. Longitudinal studies with repeated measures may compare subjects to 
themselves at time points, and/or a control group 
b.  Exclude  
i. Wrong patient population: articles that assess psychological effects of  
1. False positives 
2. Indeterminate results before work-up 
3.  ”Pre-disease states” 
4. Genetic screening 
5. Anticipating treatment other than AS/WW 
6. <50% of study population was AS/WW when not stratified 
7. No stratification by treatment type during analysis 
8. Treatment only 
a. Include if study measured an effect before onset of treatment 
ii. Non-psychological outcomes such as screening behavior or healthcare use, 
attitudes or knowledge, satisfaction with care, risk perception, lifestyle changes 
iii. Studies with only sexual functioning/relationship/intimacy outcomes 
iv. Studies of effects in family members 
v. Studies without the desired causal direction (i.e., psychological state as predictor, 
disease or exacerbation as outcome) 
vi. Grey literature (conference abstracts, dissertations), popular press articles, letters; 
reviews; commentary or editorials; non-English-language articles 
 
 
